Iovance Biotherapeutics, Inc. IOVA
11.00
0.20
1.85%
as of 25 Sep
- Market cap
- $4.9B
- P/E
- 0.0×
Follow IOVA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(53.89%) | (55.50%) | (47.51%) | (40.36%) | |
| (41.94%) | (42.88%) | (37.40%) | (31.76%) | ||
ROIC |
(64.83%) | (62.77%) | (55.59%) | (42.96%) | |
Return on Tangible Assets |
(92.48%) | (89.79%) | (75.53%) | (59.22%) | |
Average Days of Receivables |
97.31 | 114.21 | 104.48 | 114.70 | |
Free Cash Flow per Share |
(0.97) | (0.94) | (0.73) | (0.66) | |
Free Cash Flow |
(351.82) | (336.24) | (305.02) | (296.39) | |
Capital Expenditures |
(28.68) | (33.84) | (34.23) | (32.21) | |
Piotroski F-Score |
5.00 | 4.00 | 3.00 | 5.00 | |
| Other line items | |||||
Cash ROIC |
(32.21%) | (30.38%) | (26.16%) | (25.56%) | |
Accounts Receivable Turnover |
4.09 | 3.47 | 3.74 | 4.01 | |
Accounts Payable Turnover |
4.87 | 6.97 | 5.25 | 5.76 | |
Inventory Turnover |
3.39 | 3.36 | 2.79 | 3.18 | |
Average Days of Payables |
74.44 | 46.70 | 79.03 | 57.05 | |
Days of Inventory on Hand |
123.22 | 108.92 | 123.19 | 121.01 | |
Tax Rate |
0.00 | (0.01) | 0.00 | (0.01) | |
Research and Development Expense of Revenue |
118.36% | 113.95% | 100.41% | 82.38% | |
Selling, General and Administrative Expense of Revenue |
63.05% | 57.81% | 51.63% | 45.90% | |
Share Based Compensation of Revenue |
32.24% | 23.37% | 17.48% | 14.38% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.81 | 0.77 | 0.77 | 0.91 | |
Depreciation/Fixed assets |
0.34 | 0.31 | 0.30 | 0.30 | |
Capex/Depreciation |
(0.66) | (0.84) | (0.86) | (0.82) | |
Revenue per Share |
0.69 | 0.74 | 0.68 | 0.72 | |
Operating CF per Share |
(0.89) | (0.85) | (0.65) | (0.59) | |
Capex per Share |
(0.08) | (0.09) | (0.08) | (0.07) | |
Capex to Sales |
0.11 | 0.13 | 0.12 | 0.10 | |
Net Profit Margin |
(158.78%) | (148.38%) | (123.90%) | (89.09%) |
Columns are period end dates